John Zuris

Director

John Zuris is Associate Director of Editing Technologies at Editas Medicine, a genome editing company focused on using CRISPR technology to treat patients suffering from severe diseases. His group leverages Editas’s proprietary engineered AsCas12a nuclease to achieve the best editing outcome for a chosen indication. His group developed methods to achieved nearly 100% efficiency for gene disruption or gene insertion, potentially generating best-in-class cell-based medicines. Prior to joining Editas Medicine, John completed his postdoctoral training in the laboratory of Dr. David Liu (Harvard University-Broad Institute) where he developed a lipid nanoparticle delivery system for CRISPR-Cas9 which allows for highly efficient genome editing in ex vivo and in vivo applications.

Talks About
#business #lead

Preferred Locations
#NorthAmerica